Heart Failure Device Data Will Debut in Phoenix
New real-world findings on the Barostim implant will be shared at an upcoming scientific meeting.
Updated on Sept. 29, 2026 in Heart Disease
Live Poll
Do you believe new medical device innovations are effectively improving heart failure treatment outcomes?
Clinical research for the Barostim heart failure device will be highlighted during the HFSA Annual Scientific Meeting 2026, which begins October 9, 2026, in Phoenix. The presentation will feature data from the REBALANCE Registry and the BENEFIT-HF clinical trial.
Why it matters
Understanding how devices impact heart failure management is critical for patients exploring treatment options beyond standard medications. This research provides insights into how the device performs in real-world clinical settings.
The upcoming sessions will present findings from four distinct data sets, including the REBALANCE Registry, HFmrEF real-world evidence, and the BENEFIT-HF clinical trial. These presentations build on existing clinical evidence regarding the performance of the device.
The players
CVRx
A medical device company based in Minneapolis that specializes in developing implantable therapies for cardiovascular conditions.
HFSA
The Heart Failure Society of America, an organization dedicated to the study and management of heart failure.
The details
Barostim is an FDA-approved implantable device that targets the autonomic nervous system to manage heart failure symptoms. The device delivers electrical pulses to baroreceptors located in the carotid artery. This stimulation helps restore balance to the nervous system, potentially reducing the burden of heart failure symptoms for patients.
Timeline
October 9, 2026: The meeting begins with device discussion forums and posters.
October 10, 2026: Poster presentations on device interaction take place.
October 11, 2026: The schedule includes plenary sessions and rapid-fire research presentations.
October 12, 2026: The final device discussion session concludes the program.
Health Landscape
This development represents a continued expansion of evidence for baroreflex activation therapy in the broader heart failure treatment landscape. These findings sit alongside established pharmacological standards, helping to clarify the role of device-based intervention in chronic care.
If you or a loved one are currently managing heart failure, these upcoming research updates may provide new context for discussing device-based therapies with your cardiologist. It is worthwhile to ask your physician whether new registry data might inform future care decisions.
The takeaway
The upcoming conference will offer a window into how the Barostim device functions in diverse patient populations. Patients should feel encouraged to monitor for summaries of these results and discuss the clinical implications for their own heart failure management with their care team.
Further reading
For broader context on managing chronic conditions, explore our Heart Disease section.
More information
To review the latest research and information, visit the learn more about Barostim resource page.
Live Poll
Do you believe new medical device innovations are effectively improving heart failure treatment outcomes?
